Our
Products and Development Pipeline
Since its formation, biOracle
has primarily been concerned with completing development of its
early products. Commercialisation of these products started
early in 2005, with launches scheduled to take place over the
next couple of years. YeasTest, our rapid point of care
diagnostic test for vaginal candidiasis (candida overgrowth
sometimes known as thrush), is already available in
a number of countries, where it is well-received by
gynaecologists, physicians and patients alike. Clinical
evaluation of YeasTest demonstrates that it is more
effective in the diagnosis of thrush (vaginitis) than
microscopic examination and culture, currently the two most
widely used diagnostic techniques.
Further information on each product is available by following
the links below.
YeasTest - a unique point-of-care
diagnostic test for candida infections causing thrush
biO1021 - a novel point-of-care
diagnostic test for appendicitis biO1039
- a unique point-of-care diagnostic test for bacterial vaginosis biO1042
- a rapid diagnostic test to measure an important new marker of
cardiovascular disease In addition to these
products, biOracle
is exploring a number of other opportunities in the preventive
care arena.
biO1039
- a unique point-of-care diagnostic test for bacterial vaginosis Bacterial
vaginosis (BV) is a serious infection caused by an overgrowth of
anaerobic bacteria. It is one of the most common reasons for
attendance at a Genito-Urinary Medicine Clinic, and may be found
in up to 10% of the female population. Although many people
may experience no symptoms from bacterial vaginosis, it is associated with
complications in pregnancy, pelvic inflammatory disease and
transmission of other more serious infections.
Currently, diagnosis of bacterial vaginosis is most frequently carried out by
physical examination and laboratory testing, a process that can
be both time-consuming and uncomfortable for the patient. Introduction
of biOracle's
point-of-care diagnostic test for bacterial vaginosis will mean that for the first
time clinicians will be able to detect BV and initiate treatment
on a single patient visit. Similarly, after a course of
treatment, biOracle's test can be
used to demonstrate that the medication has done its job, giving
reassurance that the patient is free of the long term
consequences associated with this infection. 
biO1042
- a rapid diagnostic test to detect an important new marker of
cardiovascular disease Further details to be released
as biOracle's clinical programme
progresses.
|
